NEW YORK (GenomeWeb) – As many companies gear up to compete in the blood-based cancer detection space using technologies that analyze mutations in circulating cell-free DNA or circulating tumor cells, Belgian diagnostics firm VolitionRx has taken what it believes is a unique approach toward the same end.

The company is advancing a technology its calls NuQ for isolating and analyzing circulating nucleosomes, with its first commercial product for colon cancer scheduled for launch in Europe this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.